Differential profile analysis of urinary cytokines in patients with overactive bladder
- PMID: 21487829
- DOI: 10.1007/s00192-011-1401-8
Differential profile analysis of urinary cytokines in patients with overactive bladder
Erratum in
- Int Urogynecol J. 2011 Aug;22(8):1069
Abstract
Introduction and hypothesis: We hypothesize that overactive bladder (OAB) can produce inflammatory cytokines due to afferent neural plasticity or urothelial dysfunction. This study aimed to detect abnormal cytokine levels in urine of patients with OAB compared to urinary tract infections (UTI) and controls.
Methods: This was a prospective, single blind study including 20 premenopausal women (control), 20 with OAB and 16 with UTI. Urine samples were collected, centrifuged, and stored (-80°C). Urinary total proteins were quantified and detected by antibody-based array chip for release of 120 human cytokines in the two groups relative to the controls.
Results: Majority of cytokines showed the same expression in the OAB compared with the controls. Cytokines exclusively expressed in OAB were: monocyte chemoattractant protein (MCP) 1, TARC, PARC, and Fas/TNFRSF6. MCP-2, MCP-3, tumor necrosis factor-β, GCSF and eotaxin-3 showed a shared expression in UTI and OAB. Conversely, few of the cytokines were downregulated in OAB (IL-5, IL-6, IL-7, and GM-CSF).
Conclusions: Taken together, the results suggest that a subset of inflammatory cytokines and chemokines provides a framework for development of highly optimized urinary biomarker assay for differential diagnosis and treatment of OAB.
Comment in
-
Differential profile analysis of urinary cytokines in patients with overactive bladder: comment.Int Urogynecol J. 2012 Aug;23(8):1141; author reply 1143. doi: 10.1007/s00192-012-1684-4. Int Urogynecol J. 2012. PMID: 22638666 No abstract available.
Similar articles
-
Elevated CXC chemokines in urine noninvasively discriminate OAB from UTI.Am J Physiol Renal Physiol. 2016 Sep 1;311(3):F548-54. doi: 10.1152/ajprenal.00213.2016. Epub 2016 Jun 22. Am J Physiol Renal Physiol. 2016. PMID: 27335375
-
Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study.Int Urol Nephrol. 2010 Sep;42(3):629-35. doi: 10.1007/s11255-009-9647-5. Epub 2009 Sep 26. Int Urol Nephrol. 2010. PMID: 19784793
-
Differential profile analysis of urinary cytokines in patients with overactive bladder: comment.Int Urogynecol J. 2012 Aug;23(8):1141; author reply 1143. doi: 10.1007/s00192-012-1684-4. Int Urogynecol J. 2012. PMID: 22638666 No abstract available.
-
Recurrent Urinary Tract Infections in Females and the Overlap with Overactive Bladder.Curr Urol Rep. 2018 Sep 13;19(11):94. doi: 10.1007/s11934-018-0839-3. Curr Urol Rep. 2018. PMID: 30215140 Review.
-
[Urinary tract infection and overactive bladder. Is there an association?].Urologiia. 2024 Mar;(1):153-161. Urologiia. 2024. PMID: 38650421 Review. Russian.
Cited by
-
Urinary Tract Infection in Overactive Bladder: An Update on Pathophysiological Mechanisms.Front Physiol. 2022 Jul 4;13:886782. doi: 10.3389/fphys.2022.886782. eCollection 2022. Front Physiol. 2022. PMID: 35860658 Free PMC article. Review.
-
Inflammatory and tissue remodeling urinary biomarkers before and after mid urethral sling surgery for stress urinary incontinence.J Urol. 2014 Mar;191(3):703-9. doi: 10.1016/j.juro.2013.10.051. Epub 2013 Oct 16. J Urol. 2014. PMID: 24140551 Free PMC article.
-
Platelet-rich plasma attenuates the UPEC-induced cystitis via inhibiting MMP-2,9 activities and downregulation of NGF and VEGF in Canis Lupus Familiaris model.Sci Rep. 2024 Jun 13;14(1):13612. doi: 10.1038/s41598-024-63760-y. Sci Rep. 2024. PMID: 38871929 Free PMC article.
-
Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation versus OnabotulinumtoxinA Compared to Controls.J Urol. 2017 Jun;197(6):1487-1495. doi: 10.1016/j.juro.2017.01.037. Epub 2017 Jan 13. J Urol. 2017. PMID: 28089729 Free PMC article. Clinical Trial.
-
Fesoterodine in randomised clinical trials: an updated systematic clinical review of efficacy and safety.Int Urogynecol J. 2012 Oct;23(10):1337-44. doi: 10.1007/s00192-012-1696-0. Epub 2012 Mar 13. Int Urogynecol J. 2012. PMID: 22411206
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous